SYDNEY, Jan 8, 2026, 16:50 AEDT — Market closed
CSL Limited shares closed up 2.6% at A$174.45 on Thursday, after trading between A$172.03 and A$175.10. The stock is still down about 39% over the past year and has ranged between roughly A$168 and A$289 over that period.
The gain helped steady Australia’s heavyweight healthcare name as the S&P/ASX 200 ended up 0.3% at 8,720. The Australian dollar was about 0.3% lower at 67.02 U.S. cents in late trade.
Part of the lift came from a broader bounce in battered pockets of the market, with healthcare up about 1.2% mid-afternoon as bond yields eased for a second session. MarketIndex said Australia’s 10-year yield is down about 18 basis points since Jan. 2, a pullback it linked to Wednesday’s softer inflation print.
Some investors are also leaning on valuation calls in the sector. “Key players such as CSL, Ramsay Health Care and Sonic Healthcare remain materially undervalued,” Morningstar Australia associate investment specialist Tyger Fitzpatrick wrote on Thursday. Morningstar
Rate expectations are still doing the heavy lifting for sentiment. Reserve Bank of Australia Deputy Governor Andrew Hauser said inflation is still too high even after November’s slowdown and flagged the importance of the next quarterly CPI read for policy.
That read is not far off. The Australian Bureau of Statistics is due to publish December quarter 2025 CPI data on Wednesday, Jan. 28.
The RBA’s next policy decision is scheduled for Feb. 3 at 2:30 p.m. AEDT, after its board meets Feb. 2–3, a calendar update that could shift rate pricing again.
But CSL has its own tripwires. The company cut its fiscal 2026 revenue growth outlook and delayed the planned spin-off of its flu vaccine unit after weakness in U.S. vaccination demand, a reset that has hung over the stock since late 2025.
Related articles: ASX:CSL
